Ocular Myasthenia Gravis research hub
3 indexed studies · 1 currently recruiting
- authorisedTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
This clinical trial is testing a medicine called rozanolixizumab (Rystiggo) for adults with ocular myasthenia gravis. This condition causes eye muscle weakness, leading to droopy eyelids and double vision. Researchers want to see if this injection reduces eye symptoms and improves daily life compared to a dummy treatment (placebo).
Hungary · Greece · Italy - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis
This clinical trial tests a medicine called rozanolixizumab (Rystiggo) for adults with ocular myasthenia gravis. This condition causes eye muscle weakness, leading to drooping eyelids and double vision. Researchers want to find out how safe and effective this medicine is when used over a longer period.
Hungary · France · Greece - recruitingPHASE3
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
This study looks at new ways to treat Ocular Myasthenia Gravis (OMG). We're testing if starting steroid treatment sooner and adding another medicine (rituximab) helps stop the condition from getting worse and affecting other muscles.
France